Search
More Health Overview
Working at the intersection of human and animal health, we have unique opportunities to positively impact vulnerable populations.
China: Biosecurity to fight African swine fever
Animal health team in China has been recognized for their initiatives to help customers combat African swine fever (ASF)
Making more health through animal health
Boehringer Ingelheim and Ashoka aim to build a world with a greater access to health for people, animals and their communities.
Micardis®
Treatment of hypertension. For the reduction of the risk of myocardial infarction (heart attack), stroke or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take A
Boehringer Ingelheim Launches New Arabic Website to Support Patients Living with Idiopathic
Boehringer Ingelheim Launches New Arabic Website to Support Patients Living with Idiopathic Pulmonary Fibrosis in the Region
Lameness – a common problem in horses
The causes of lameness, and why there is a clear need for innovation and new treatment options.
Cattle well-being at farms’ core
From pain management to responsible use of antibiotics, Cattle First introduces a whole cow approach to look after health and productivity.
Pulmonary Fibrosis Awareness Month 2020
Hear what Peter Fang said about pulmonary fibrosis awareness month, our commitment to advancing care and our engaging new campaign, ‘the most important postcard you will ever write’
Illuminating Connections, Inspiring Hope
Illuminating Connections, Inspiring Hope is a public awareness and engagement initiative launched by Boehringer Ingelheim in collaboration with the Dubai Health Authority. It aims to raise awareness of the interconnectivity between cardiovascular, renal,
Three challenges shape future antiparasitic treatment
The three key challenges that will shape the future of antiparasitic treatment
Human-dog relationship – a historical perspective
The human-dog relationship – a historical perspective
Research Beyond Borders overview
Learn more about how our Research Beyond Borders team is uncovering new ideas and new science.
Technologies
We are expanding our global network of technology partners Learn more about partnering with us.
Rabies wildlife 5 things to know
Rabies in wildlife - 5 things to know to protect yourself and your pet
KidZania, Purina, & Boehringer Ingelheim Promote Veterinary Career Paths & Pet Health in Dubai
KidZania, Purina, & Boehringer Ingelheim Promote Veterinary Career Paths & Pet Health in Dubai
The Angels Initiative
Regional experts highlight need for coordinated, collaborative efforts in stroke care through
Regional experts highlight need for coordinated, collaborative efforts in stroke care through dedicated hospital unitsRegional experts highlight need for coordinated, collaborative efforts in stroke care through dedicated hospital units
World Stroke Organization Honors Eight Stroke Centers powered by Angels Award for their Efforts in developing stroke management in Egypt
World Stroke Organization Honors Eight Stroke Centers powered by Angels Award
All hands-on deck to fight the ‘zombie’ rabies virus
We’re teaming up with communities and governments across Southeast Asia to fight rabies through vaccinations, education programs, and partnerships.
Our Innovation Strategy
Our discovery research strategy is designed to sustain our track record of innovation and look for new and breakthrough medicines.
Improving Access to Healthcare
According to the UN Sustainable Development Goals, almost half of the global population is not covered by essential health services.
Our Approach
We are driven by the desire to improve human and animal health -– now and in the future. Therefore, we have developed our framework: Sustainable Development – For Generations.
2019 performance: stronger foundation to absorb global effects of COVID-19 pandemic
2019 performance: stronger foundation to absorb global effects of COVID-19 pandemic
Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study
Topline data from FIBRONEER™-IPF show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline in Forced Vital Capacity [mL] at week 52 versus placebo.